Literature DB >> 33782098

POT1 Regulates Proliferation and Confers Sexual Dimorphism in Glioma.

Ali Jalali1, Kwanha Yu1,2, Vivek Beechar2, Navish A Bosquez Huerta2,3, Anthony Grichuk1, Deepika Mehra1, Brittney Lozzi2, Kathleen Kong2, Kenneth L Scott4, Ganesh Rao1, Matthew N Bainbridge5, Melissa L Bondy6, Benjamin Deneen7,2,3.   

Abstract

Germline POT1 mutations are found in a spectrum of cancers and confer increased risk. Recently, we identified a series of novel germline POT1 mutations that predispose carrier families to the development of glioma. Despite these strong associations, how these glioma-associated POT1 mutations contribute to glioma tumorigenesis remains undefined. Here we show that POT1-G95C increases proliferation in glioma-initiating cells in vitro and in progenitor populations in the developing brain. In a native mouse model of glioma, loss of Pot1a/b resulted in decreased survival in females compared with males. These findings were corroborated in human glioma, where low POT1 expression correlated with decreased survival in females. Transcriptomic and IHC profiling of Pot1a/b-deficient glioma revealed that tumors in females exhibited decreased expression of immune markers and increased expression of cell-cycle signatures. Similar sex-dependent trends were observed in human gliomas that had low expression of POT1. Together, our studies demonstrate context-dependent functions for POT1 mutation or loss in driving progenitor proliferation in the developing brain and sexual dimorphism in glioma. SIGNIFICANCE: This study shows that manipulation of POT1 expression in glioma has sex-specific effects on tumorigenesis and associated immune signatures. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33782098      PMCID: PMC8243722          DOI: 10.1158/0008-5472.CAN-20-3755

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Unmasking senescence: context-dependent effects of SASP in cancer.

Authors:  Douglas V Faget; Qihao Ren; Sheila A Stewart
Journal:  Nat Rev Cancer       Date:  2019-06-24       Impact factor: 60.716

Review 2.  Telomere dysfunction and tumour suppression: the senescence connection.

Authors:  Yibin Deng; Suzanne S Chan; Sandy Chang
Journal:  Nat Rev Cancer       Date:  2008-06       Impact factor: 60.716

3.  POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families.

Authors:  Erica Shen; Joanne Xiu; Giselle Y Lopez; Rex Bentley; Ali Jalali; Amy B Heimberger; Matthew N Bainbridge; Melissa L Bondy; Kyle M Walsh
Journal:  J Med Genet       Date:  2020-01-14       Impact factor: 6.318

4.  Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers.

Authors:  Michael Prosniak; Larry A Harshyne; David W Andrews; Lawrence C Kenyon; Kamila Bedelbaeva; Tatiyana V Apanasovich; Ellen Heber-Katz; Mark T Curtis; Paolo Cotzia; D Craig Hooper
Journal:  Clin Cancer Res       Date:  2013-06-05       Impact factor: 12.531

5.  Identification of diverse astrocyte populations and their malignant analogs.

Authors:  Chia-Ching John Lin; Kwanha Yu; Asante Hatcher; Teng-Wei Huang; Hyun Kyoung Lee; Jeffrey Carlson; Matthew C Weston; Fengju Chen; Yiqun Zhang; Wenyi Zhu; Carrie A Mohila; Nabil Ahmed; Akash J Patel; Benjamin R Arenkiel; Jeffrey L Noebels; Chad J Creighton; Benjamin Deneen
Journal:  Nat Neurosci       Date:  2017-02-06       Impact factor: 24.884

6.  Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

Authors:  Justyna Kmiecik; Aurélie Poli; Nicolaas H C Brons; Andreas Waha; Geir Egil Eide; Per Øyvind Enger; Jacques Zimmer; Martha Chekenya
Journal:  J Neuroimmunol       Date:  2013-08-31       Impact factor: 3.478

7.  POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.

Authors:  Andrew J Ramsay; Víctor Quesada; Miguel Foronda; Laura Conde; Alejandra Martínez-Trillos; Neus Villamor; David Rodríguez; Agnieszka Kwarciak; Cecilia Garabaya; Mercedes Gallardo; Mónica López-Guerra; Armando López-Guillermo; Xose S Puente; María A Blasco; Elías Campo; Carlos López-Otín
Journal:  Nat Genet       Date:  2013-03-17       Impact factor: 38.330

Review 8.  Shelterin: the protein complex that shapes and safeguards human telomeres.

Authors:  Titia de Lange
Journal:  Genes Dev       Date:  2005-09-15       Impact factor: 12.890

9.  Telomere Replication Stress Induced by POT1 Inactivation Accelerates Tumorigenesis.

Authors:  Alexandra M Pinzaru; Robert A Hom; Angela Beal; Aaron F Phillips; Eric Ni; Timothy Cardozo; Nidhi Nair; Jaehyuk Choi; Deborah S Wuttke; Agnel Sfeir; Eros Lazzerini Denchi
Journal:  Cell Rep       Date:  2016-05-26       Impact factor: 9.423

10.  A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.

Authors:  Oriol Calvete; Paula Martinez; Pablo Garcia-Pavia; Carlos Benitez-Buelga; Beatriz Paumard-Hernández; Victoria Fernandez; Fernando Dominguez; Clara Salas; Nuria Romero-Laorden; Jesus Garcia-Donas; Jaime Carrillo; Rosario Perona; Juan Carlos Triviño; Raquel Andrés; Juana María Cano; Bárbara Rivera; Luis Alonso-Pulpon; Fernando Setien; Manel Esteller; Sandra Rodriguez-Perales; Gaelle Bougeard; Tierry Frebourg; Miguel Urioste; Maria A Blasco; Javier Benítez
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 17.694

View more
  2 in total

1.  Proteome alterations during clonal isolation of established human pancreatic cancer cell lines.

Authors:  P Bernhard; T Feilen; M Rogg; K Fröhlich; M Cosenza-Contreras; F Hause; C Schell; O Schilling
Journal:  Cell Mol Life Sci       Date:  2022-10-22       Impact factor: 9.207

2.  Serum microRNA-4297 is a sex-specific predictive biomarker of glioma grade and prognosis.

Authors:  Wenshen Xu; Liming Huang; Bingsen Xie; Bin Yang
Journal:  Front Neurol       Date:  2022-07-27       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.